<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>486</ReferenceId>
        <DateLastUpdated>2020-09-10-07:00</DateLastUpdated>
        <Article>
            <PubmedId>15542798</PubmedId>
            <Abstract>PURPOSE: A phase II trial was performed to test whether systemic low-dose interleukin-2 (IL-2) augments T-cell immune responses to a multipeptide melanoma vaccine. Forty patients with resected stage IIB-IV melanoma were randomly assigned to vaccination with four gp100- and tyrosinase-derived peptides restricted by human leukocyte antigen (HLA) -A1, HLA-A2, and HLA-A3, and a tetanus helper peptide plus IL-2 administered daily either beginning day 7 (group 1), or beginning day 28 (group 2). PATIENTS AND METHODS: T-cell responses were assessed by an interferon gamma ELIspot assay in peripheral blood lymphocytes (PBL) and in a lymph node draining a vaccination site (sentinel immunized node [SIN]). Patients were followed for disease-free and overall survival. RESULTS: T-cell responses to the melanoma peptides were observed in 37% of PBL and 38% of SINs in group 1, and in 53% of PBL and 83% of SINs in group 2. The magnitude of T-cell response was higher in group 2. The tyrosinase peptides DAEKSDICTDEY and YMDGTMSQV were more immunogenic than the gp100 peptides YLEPGPVTA and ALLAVGATK. T-cell responses were detected in the SINs more frequently, and with higher magnitude, than responses in the PBL. Disease-free survival estimates at 2 years were 39% (95% CI, 18% to 61%) for group 1, and 50% (95% CI, 28% to 72%) for group 2 (P = .32). CONCLUSION: The results of this study support the safety and immunogenicity of a vaccine composed of four peptides derived from gp100 and tyrosinase. The low-dose IL-2 regimen used for group 1 paradoxically diminishes the magnitude and frequency of cytotoxic T lymphocyte responses to these peptides.</Abstract>
            <ArticleYear>2004</ArticleYear>
            <ArticlePages>4474-85</ArticlePages>
            <ArticleTitle>Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Slingluff</LastName>
                    <ForeName>Craig L</ForeName>
                    <Suffix>Jr</Suffix>
                </Author>
                <Author>
                    <LastName>Petroni</LastName>
                    <ForeName>Gina R</ForeName>
                </Author>
                <Author>
                    <LastName>Yamshchikov</LastName>
                    <ForeName>Galina V</ForeName>
                </Author>
                <Author>
                    <LastName>Hibbitts</LastName>
                    <ForeName>Sarah</ForeName>
                </Author>
                <Author>
                    <LastName>Grosh</LastName>
                    <ForeName>William W</ForeName>
                </Author>
                <Author>
                    <LastName>Chianese-Bullock</LastName>
                    <ForeName>Kimberly A</ForeName>
                </Author>
                <Author>
                    <LastName>Bissonette</LastName>
                    <ForeName>Eric A</ForeName>
                </Author>
                <Author>
                    <LastName>Barnd</LastName>
                    <ForeName>Donna L</ForeName>
                </Author>
                <Author>
                    <LastName>Deacon</LastName>
                    <ForeName>Donna H</ForeName>
                </Author>
                <Author>
                    <LastName>Patterson</LastName>
                    <ForeName>James W</ForeName>
                </Author>
                <Author>
                    <LastName>Parekh</LastName>
                    <ForeName>Jayashree</ForeName>
                </Author>
                <Author>
                    <LastName>Neese</LastName>
                    <ForeName>Patrice Y</ForeName>
                </Author>
                <Author>
                    <LastName>Woodson</LastName>
                    <ForeName>Elizabeth M H</ForeName>
                </Author>
                <Author>
                    <LastName>Wiernasz</LastName>
                    <ForeName>Catherine J</ForeName>
                </Author>
                <Author>
                    <LastName>Merrill</LastName>
                    <ForeName>Priscilla</ForeName>
                </Author>
            </Authors>
            <ArticleChemicalList>Antineoplastic Agents;Cancer Vaccines;HLA Antigens;Interleukin-2;Membrane Glycoproteins;Neoplasm Proteins;PMEL protein, human;Vaccines, Subunit;gp100 Melanoma Antigen;Tyrosine</ArticleChemicalList>
            <ArticleMeshHeadingsList>Adult; Aged; Antineoplastic Agents(administration &amp; dosage; pharmacology); Cancer Vaccines(administration &amp; dosage; immunology; pharmacology); Disease-Free Survival; Drug Administration Schedule; Female; HLA Antigens(immunology); Humans; Interleukin-2(administration &amp; dosage; pharmacology); Male; Melanoma(drug therapy; immunology); Membrane Glycoproteins(immunology); Middle Aged; Neoplasm Proteins(immunology); Skin Neoplasms(drug therapy; immunology); Treatment Outcome; Tyrosine(immunology); Vaccines, Subunit(administration &amp; dosage; immunology; pharmacology); gp100 Melanoma Antigen</ArticleMeshHeadingsList>
            <Comments>16051975  J Clin Oncol. 2005 Aug 1;23(22):5265-7; author reply 5267-8</Comments>
            <Journal>
                <Volume>22</Volume>
                <Issue>22</Issue>
                <Title>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</Title>
                <Issn>1527-7755</Issn>
                <MedlineTa>J Clin Oncol</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>DAEK</EpitopeName>
                <EpitopeStructure>
                    <SequenceMoleculeNoNaturalSource>
                        <ChemicalType>Peptide, no natural source</ChemicalType>
                        <LinearSequence>DAEKSDICTDEY</LinearSequence>
                    </SequenceMoleculeNoNaturalSource>
                </EpitopeStructure>
                <LocationOfData>Patients and Methods</LocationOfData>
                <EpitopeId>7497</EpitopeId>
                <ReferenceStartingPosition>240</ReferenceStartingPosition>
                <ReferenceEndingPosition>251</ReferenceEndingPosition>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>Authors state this is an HLA-A1-restricted epitope.  Epitope used in study has a C244S substitution.</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Figures 4A and 4B</LocationOfData>
                        <TCellId>3295</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of cancer</InVivoProcessType>
                                <DiseaseState>DOID:8923</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                            </FirstInVivoProcess>
                            <SecondInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <SequenceMoleculeNoNaturalSource>
                                            <ChemicalType>Peptide, no natural source</ChemicalType>
                                            <LinearSequence>DAEKSDICTDEY</LinearSequence>
                                        </SequenceMoleculeNoNaturalSource>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>DAEK</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>GM-CSF</Adjuvant>
                                <Adjuvant>Montanide ISA-51</Adjuvant>
                                <Adjuvant>IL-2</Adjuvant>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>Vaccine administered on weeks 0, 1, 2, 4, 5, and 6.  At each injection site, 1/2 dose was s.c. and 1/2 dose i.d.  Patients self-administered IL-2 daily for 6 weeks Group I: upfront IL-2 (days 7-49); Group II delayed IL-2 (days 27-70).</DoseSchedule>
                            </SecondInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                                <ResponderCellType>PBMC</ResponderCellType>
                                <StimulatorCellType>PBMC</StimulatorCellType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <SequenceMoleculeNoNaturalSource>
                                            <ChemicalType>Peptide, no natural source</ChemicalType>
                                            <LinearSequence>DAEKSDICTDEY</LinearSequence>
                                        </SequenceMoleculeNoNaturalSource>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </InVitroAdministration>
                            <ImmunizationComments>Patients with resected stage IIB-IV melanoma, whose melanoma cells expressed gp100 and/or tyrosinase as determined by immunohistochemistry, were studied in a phase II trial was performed to test whether systemic low-dose interleukin-2 (IL-2) augments T-cell immune responses to a multipeptide ( with gp100- and tyrosinase-derived peptides)  melanoma vaccine. Vaccinations were carried out as mixture containing four peptides.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>PBMC</CellType>
                            <CellCultureConditions>Short Term Restimulated</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>PBMC</CellType>
                            <CellCultureConditions>Short Term Restimulated</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>233</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>DAEK</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <SequenceMoleculeNoNaturalSource>
                                        <ChemicalType>Peptide, no natural source</ChemicalType>
                                        <LinearSequence>DAEKSDICTDEY</LinearSequence>
                                    </SequenceMoleculeNoNaturalSource>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>14</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>13</NumberOfSubjectsResponded>
                            <ResponseFrequency>92.9</ResponseFrequency>
                            <AssayComments>Sentinel Immunized nodes (SINs) were also analyzed by ELISPOT, demonstrating that IL-2 diminishes the magnitude and frequency of CTL responses.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>YLE</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>YLEPGPVTA</LinearSequence>
                        <StartingPosition>280</StartingPosition>
                        <EndingPosition>288</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P40967.2</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>9606</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Patients and Methods</LocationOfData>
                <EpitopeId>74638</EpitopeId>
                <ReferenceStartingPosition>280</ReferenceStartingPosition>
                <ReferenceEndingPosition>288</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>Authors state this is an HLA-A2-restricted epitope.</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Figures 4A and 4B</LocationOfData>
                        <TCellId>3408</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of cancer</InVivoProcessType>
                                <DiseaseState>DOID:8923</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                            </FirstInVivoProcess>
                            <SecondInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>YLEPGPVTA</LinearSequence>
                                            <StartingPosition>280</StartingPosition>
                                            <EndingPosition>288</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P40967.2</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>YLE</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>GM-CSF</Adjuvant>
                                <Adjuvant>Montanide ISA-51</Adjuvant>
                                <Adjuvant>IL-2</Adjuvant>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>Vaccine administered on weeks 0, 1, 2, 4, 5, and 6.  At each injection site, 1/2 dose was s.c. and 1/2 dose i.d.  Patients self-administered IL-2 daily for 6 weeks Group I: upfront IL-2 (days 7-49); Group II delayed IL-2 (days 27-70).</DoseSchedule>
                            </SecondInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                                <ResponderCellType>PBMC</ResponderCellType>
                                <StimulatorCellType>PBMC</StimulatorCellType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>YLEPGPVTA</LinearSequence>
                                            <StartingPosition>280</StartingPosition>
                                            <EndingPosition>288</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P40967.2</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                            </InVitroAdministration>
                            <ImmunizationComments>Patients with resected stage IIB-IV melanoma, whose melanoma cells expressed gp100 and/or tyrosinase as determined by immunohistochemistry, were studied in a phase II trial was performed to test whether systemic low-dose interleukin-2 (IL-2) augments T-cell immune responses to a multipeptide ( with gp100- and tyrosinase-derived peptides)  melanoma vaccine. Vaccinations were carried out as mixture containing four peptides.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>PBMC</CellType>
                            <CellCultureConditions>Short Term Restimulated</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>PBMC</CellType>
                            <CellCultureConditions>Short Term Restimulated</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>235</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>YLE</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>YLEPGPVTA</LinearSequence>
                                        <StartingPosition>280</StartingPosition>
                                        <EndingPosition>288</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P40967.2</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>7</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>4</NumberOfSubjectsResponded>
                            <ResponseFrequency>57.1</ResponseFrequency>
                            <AssayComments>Sentinel Immunized nodes (SINs) were also analyzed by ELISPOT, demonstrating that IL-2 diminishes the magnitude and frequency of CTL responses.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>YMD</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>YMDGTMSQV</LinearSequence>
                        <SourceMolecule>
                            <IedbAccession>SRC279957</IedbAccession>
                        </SourceMolecule>
                        <SourceOrganismId>9606</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Patients and Methods</LocationOfData>
                <EpitopeId>75043</EpitopeId>
                <ReferenceStartingPosition>369</ReferenceStartingPosition>
                <ReferenceEndingPosition>377</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Internal Identifier-no external match available</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>Authors state this is an HLA-A2-restricted epitope.  Epitope used in this study contained N371D substitution.</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Figures 4A and 4B</LocationOfData>
                        <TCellId>3412</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of cancer</InVivoProcessType>
                                <DiseaseState>DOID:8923</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                            </FirstInVivoProcess>
                            <SecondInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>YMDGTMSQV</LinearSequence>
                                            <SourceMolecule>
                                                <IedbAccession>SRC279957</IedbAccession>
                                            </SourceMolecule>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>YMD</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>GM-CSF</Adjuvant>
                                <Adjuvant>Montanide ISA-51</Adjuvant>
                                <Adjuvant>IL-2</Adjuvant>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>Vaccine administered on weeks 0, 1, 2, 4, 5, and 6.  At each injection site, 1/2 dose was s.c. and 1/2 dose i.d.  Patients self-administered IL-2 daily for 6 weeks Group I: upfront IL-2 (days 7-49); Group II delayed IL-2 (days 27-70).</DoseSchedule>
                            </SecondInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                                <ResponderCellType>PBMC</ResponderCellType>
                                <StimulatorCellType>PBMC</StimulatorCellType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>YMDGTMSQV</LinearSequence>
                                            <SourceMolecule>
                                                <IedbAccession>SRC279957</IedbAccession>
                                            </SourceMolecule>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                            </InVitroAdministration>
                            <ImmunizationComments>Patients with resected stage IIB-IV melanoma, whose melanoma cells expressed gp100 and/or tyrosinase as determined by immunohistochemistry, were studied in a phase II trial was performed to test whether systemic low-dose interleukin-2 (IL-2) augments T-cell immune responses to a multipeptide ( with gp100- and tyrosinase-derived peptides)  melanoma vaccine. Vaccinations were carried out as mixture containing four peptides.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>PBMC</CellType>
                            <CellCultureConditions>Short Term Restimulated</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>PBMC</CellType>
                            <CellCultureConditions>Short Term Restimulated</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>235</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>YMD</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>YMDGTMSQV</LinearSequence>
                                        <SourceMolecule>
                                            <IedbAccession>SRC279957</IedbAccession>
                                        </SourceMolecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>13</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>10</NumberOfSubjectsResponded>
                            <ResponseFrequency>76.9</ResponseFrequency>
                            <AssayComments>Sentinel Immunized nodes (SINs) were also analyzed by ELISPOT, demonstrating that IL-2 diminishes the magnitude and frequency of CTL responses.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>ALLA</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>ALLAVGATK</LinearSequence>
                        <StartingPosition>17</StartingPosition>
                        <EndingPosition>25</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P40967.2</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>9606</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Patients and Methods</LocationOfData>
                <EpitopeId>2688</EpitopeId>
                <ReferenceStartingPosition>17</ReferenceStartingPosition>
                <ReferenceEndingPosition>25</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>Authors state this is an HLA-A3-restricted epitope.</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Figures 4A and 4B</LocationOfData>
                        <TCellId>3416</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of cancer</InVivoProcessType>
                                <DiseaseState>DOID:8923</DiseaseState>
                                <DiseaseStage>Post</DiseaseStage>
                            </FirstInVivoProcess>
                            <SecondInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>ALLAVGATK</LinearSequence>
                                            <StartingPosition>17</StartingPosition>
                                            <EndingPosition>25</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P40967.2</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>ALLA</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Adjuvant>GM-CSF</Adjuvant>
                                <Adjuvant>Montanide ISA-51</Adjuvant>
                                <Adjuvant>IL-2</Adjuvant>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>Vaccine administered on weeks 0, 1, 2, 4, 5, and 6.  At each injection site, 1/2 dose was s.c. and 1/2 dose i.d.  Patients self-administered IL-2 daily for 6 weeks Group I: upfront IL-2 (days 7-49); Group II delayed IL-2 (days 27-70).</DoseSchedule>
                            </SecondInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                                <ResponderCellType>PBMC</ResponderCellType>
                                <StimulatorCellType>PBMC</StimulatorCellType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>ALLAVGATK</LinearSequence>
                                            <StartingPosition>17</StartingPosition>
                                            <EndingPosition>25</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P40967.2</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                            </InVitroAdministration>
                            <ImmunizationComments>Patients with resected stage IIB-IV melanoma, whose melanoma cells expressed gp100 and/or tyrosinase as determined by immunohistochemistry, were studied in a phase II trial was performed to test whether systemic low-dose interleukin-2 (IL-2) augments T-cell immune responses to a multipeptide ( with gp100- and tyrosinase-derived peptides)  melanoma vaccine. Vaccinations were carried out as mixture containing four peptides.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>PBMC</CellType>
                            <CellCultureConditions>Short Term Restimulated</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>PBMC</CellType>
                            <CellCultureConditions>Short Term Restimulated</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>242</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>ALLA</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>ALLAVGATK</LinearSequence>
                                        <StartingPosition>17</StartingPosition>
                                        <EndingPosition>25</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P40967.2</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>6</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>3</NumberOfSubjectsResponded>
                            <ResponseFrequency>50</ResponseFrequency>
                            <AssayComments>Sentinel Immunized nodes (SINs) were also analyzed by ELISPOT, demonstrating that IL-2 diminishes the magnitude and frequency of CTL responses.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

